Precision-Guided Dosing

[LOGO] PredictrPK (R)

PredictrPK® Ordering Logistics

Ordering PredictrPK is simple. The first step is to download the current test requisition and fill it out completely for your patient.

Scheduling a blood draw

  1. Follow the procedures your office has in place for referring patients to have their blood drawn for Prometheus testing.
  2. If you don’t have a process in place, advise your patient to call Prometheus Client Services at 888-423-5227, Monday through Friday, 6:00 am – 4:30 pm Pacific Time, to find a designated blood draw site in their area, if available.
  3. If there is not a draw site in the area, mobile phlebotomy may be available. Advise your patient to call 888-423-5227, option 5 to schedule a mobile draw, or an appointment can be scheduled online by clicking here. For questions about the scheduling process, please contact Prometheus Client Services for assistance.
  4. Important: Provide your patient with a fully completed test requisition and a copy of the front and back of their insurance card(s). Please remind them to give these items to the lab or mobile phlebotomist when their sample is collected.

Specimen Collection & Shipping Instructions

Please see the back of the test requisition for more information.

Turnaround Time 3 business days from date of receipt
Transport Requirements: Ambient or refrigerated cold pack (do not freeze)
Specimen Type & Volume: 2.0 mL serum (0.5 mL for peds)
Specimen Collection Tube: Serum Separator Tube or Red-Top Tube
Specimen Stability: 14 days room temperature and 14 days refrigerated

PredictrPK Sample Collection Window

Here are the guidelines for when to collect a specimen for PredictrPK. You can also use our calculator to determine the precise window for your patient.

PredictrPK IFX Induction Validated for adult and pediatric IBD patients
Serum must be collected ≤3 days prior to IV infliximab dose 3
PredictrPK IFX Maintenance Validated for adult and pediatric IBD patients
Serum can be collected ≤3 days prior to week 14, or ≥20 days after any IV infliximab maintenance infusion, including and up to trough
PredictrPK ADA Maintenance Validated for adult and pediatric IBD patients ≥12 years of age
Serum can be collected at any time after 8 weeks of continuous adalimumab therapy
PredictrPK VDZ Maintenance Validated for adult IBD patients ≥18 years of age
Serum can be collected ≤3 days prior to week 14, or ≥20 days after any 300 mg vedolizumab maintenance infusion, including and up to trough
PredictrPK UST Maintenance Validated for adult IBD patients ≥18 years of age
Serum can be collected ≤3 days prior to week 16, or ≥20 days after any 90 mg ustekinumab maintenance dose, including and up to trough
Infliximab Induction and Maintenance Web Button.
Adalimumab Maintenance Web Button
Ustekinumab Maintenance web button.

PredictrPK is part of the Prometheus continuum of care for IBD patients

IBD Precis Continuum Graphic
Respondr TNF Continuum Graphic
PredictrPK continuum graphic
Anser continuum graphic

PredictrPK tests are laboratory-developed tests that were developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and are performed exclusively in our high complexity CLIA-certified (05D0917432) and College of American Pathologists-accredited (6805501) clinical laboratory. As laboratory developed tests, they have not been cleared or approved by the US FDA. These tests may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. PredictrPK IFX Maintenance and IFX Induction tests are validated for IBD patients receiving intravenous IFX. PredictrPK ADA is validated for IBD patients ≥12 years old. PredictrPK VDZ (intravenous only) and UST Maintenance are validated for IBD patients ≥18 years. Prometheus, IBD Precis, Anser, PredictrPK and Respondr are trademarks or registered trademarks of Prometheus Laboratories Inc. All other trademarks or service marks are the property of their respective owners.This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.